The liver has a unique adaptive response to continuous nutritional support (NS). The liver switches from a site of modest glucose uptake and glycogen storage to an organ that efficiently converts glucose to lactate (i.e. enhanced glycolytic capacity). As a consequence of this shift in hepatic metabolic flux we hypothesize the normal regulators of liver glucose uptake and disposition in the acute setting (glucose and insulin levels and route of glucose delivery) no longer exert the same degree of control in the adapted setting. We believe the fall in glucagon during NS is essential to allowing the adaptation to occur. The enhanced hepatic glucose disposition observed in the adapted setting decreases the fraction of the exogenous glucose removed by peripheral tissues, while still preserving total carbohydrate uptake (glucose + lactate) by peripheral tissues. Following chronic NS greater than 1/3 of the peripheral carbohydrate uptake is as lactate. Since lactate is more efficiently cleared than glucose and less dependent upon insulin for its removal and the absolute rate of glucose uptake by peripheral tissues is diminished, the insulin and glucose concentrations are decreased as well. Infection impairs this adaptive response despite compensatory hyperinsulinemia with the liver reverting back to a state similar to the un-adapted (i.e. acute) state. The failure to adapt shifts the responsibility of glucose removal to peripheral tissues. When combined with the infection induced peripheral insulin resistance the risk of developing hyperglycemia increases. We believe the infection induced rise in glucagon contributes to this impaired adaptive response and aggravates the peripheral insulin resistance. Moreover, while the presence of compensatory hyperinsulinemia and/or hyperglycemia or enteral (or portal vein) glucose delivery can acutely correct the impairment in liver glucose uptake, we hypothesize this can not be sustained because they can not overcome the deficit in hepatic glycolytic capacity. The questions we will address are. Does the suppression of glucagon secretion play an essential role in facilitating the metabolic response to NS and does its failure to suppress during infection contribute to the abnormal hepatic and peripheral metabolism? Are the compensatory hyperinsulinemia and hyperglycemia during infection able to sustain the adaptive response to NS? Do cytokines released during infection modify the adaptive response to NS? Does infection impair the ability of portal and enteral glucose delivery to facilitate liver glucose uptake and inhibit peripheral glucose uptake during NS? Experiments will be carried out in chronically catheterized conscious dogs receiving continuous nutritional support. Hepatic glucose metabolism (unidirectional hepatic glucose uptake and production, glucose oxidation) will be assessed using a combination of tracer and arterio-venous difference techniques. In addition we will simultaneously assess limb glucose uptake and disposal. While previous work has examined the response of whole body glucose metabolism to infection, our model provides the unique ability to directly examine the role that individual organs (liver and muscle) play in the infection-induced modulation of nutrient disposition and the factors responsible for the impairment and the mechanisms by which they occur.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK043748-16
Application #
7284252
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Laughlin, Maren R
Project Start
1992-02-01
Project End
2009-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
16
Fiscal Year
2007
Total Cost
$435,931
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Physiology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Rossi, Mario; Zhu, Lu; McMillin, Sara M et al. (2018) Hepatic Gi signaling regulates whole-body glucose homeostasis. J Clin Invest 128:746-759
Boortz, Kayla A; Syring, Kristen E; Pound, Lynley D et al. (2017) Effects of G6pc2 deletion on body weight and cholesterol in mice. J Mol Endocrinol 58:127-139
Boortz, Kayla A; Syring, Kristen E; Dai, Chunhua et al. (2016) G6PC2 Modulates Fasting Blood Glucose In Male Mice in Response to Stress. Endocrinology 157:3002-8
Syring, Kristen E; Boortz, Kayla A; Oeser, James K et al. (2016) Combined Deletion of Slc30a7 and Slc30a8 Unmasks a Critical Role for ZnT8 in Glucose-Stimulated Insulin Secretion. Endocrinology 157:4534-4541
Dooley, James; Garcia-Perez, Josselyn E; Sreenivasan, Jayasree et al. (2016) The microRNA-29 Family Dictates the Balance Between Homeostatic and Pathological Glucose Handling in Diabetes and Obesity. Diabetes 65:53-61
Boortz, Kayla A; Syring, Kristen E; Lee, Rebecca A et al. (2016) G6PC2 Modulates the Effects of Dexamethasone on Fasting Blood Glucose and Glucose Tolerance. Endocrinology 157:4133-4145
Otero, Yolanda F; Mulligan, Kimberly X; Barnes, Tammy M et al. (2016) Enhanced Glucose Transport, but not Phosphorylation Capacity, Ameliorates Lipopolysaccharide-Induced Impairments in Insulin-Stimulated Muscle Glucose Uptake. Shock 45:677-85
House 2nd, Lawrence M; Morris, Robert T; Barnes, Tammy M et al. (2015) Tissue inflammation and nitric oxide-mediated alterations in cardiovascular function are major determinants of endotoxin-induced insulin resistance. Cardiovasc Diabetol 14:56
Kolumam, Ganesh; Chen, Mark Z; Tong, Raymond et al. (2015) Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/?Klotho Complex. EBioMedicine 2:730-43
Cyphert, Travis J; Morris, Robert T; House, Lawrence M et al. (2015) NF-?B-dependent airway inflammation triggers systemic insulin resistance. Am J Physiol Regul Integr Comp Physiol 309:R1144-52

Showing the most recent 10 out of 24 publications